ERBB3 and gastric cancer: Our finding of a longer recurrence-free survival in I-type cases with high HER3 expression is unexpected, given the oncogenic features of HER3, and in contrast with previous reports on various non-gastrointestinal cancers [31], one on colon cancer [57], and two on gastric cancer [58, 59], but harmonize with a few studies on breast [34], colorectal [32, 33], and gastric and oesophageal cancer [35].